90B Stock Overview
Operates as a cloud-native software technology company in the healthcare space. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SOPHiA GENETICS SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.00 |
| 52 Week High | US$5.10 |
| 52 Week Low | US$2.86 |
| Beta | 1.03 |
| 11 Month Change | 0% |
| 3 Month Change | -4.46% |
| 1 Year Change | -9.64% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 90B | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -14.3% | -0.6% | -1.3% |
| 1Y | -9.6% | -33.0% | 7.4% |
Return vs Industry: 90B exceeded the German Healthcare Services industry which returned -33% over the past year.
Return vs Market: 90B underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 90B volatility | |
|---|---|
| 90B Average Weekly Movement | 11.7% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 90B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 90B's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 430 | Jurgi Camblong | www.sophiagenetics.com |
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
SOPHiA GENETICS SA Fundamentals Summary
| 90B fundamental statistics | |
|---|---|
| Market cap | €199.70m |
| Earnings (TTM) | -€68.56m |
| Revenue (TTM) | €61.93m |
3.3x
P/S Ratio-3.0x
P/E RatioIs 90B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 90B income statement (TTM) | |
|---|---|
| Revenue | US$64.49m |
| Cost of Revenue | US$20.75m |
| Gross Profit | US$43.73m |
| Other Expenses | US$115.13m |
| Earnings | -US$71.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 67.82% |
| Net Profit Margin | -110.71% |
| Debt/Equity Ratio | 11.6% |
How did 90B perform over the long term?
See historical performance and comparison